e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Prognostic factors for lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
R. Pozo Rivas, R. Alonso Moralejo, R. García Luján, P. Benavides Mañas, A. López Encuentra (Madrid, Spain)
Source:
Annual Congress 2010 - Prognostic factors for lung cancer
Session:
Prognostic factors for lung cancer
Session type:
Thematic Poster Session
Number:
3222
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Pozo Rivas, R. Alonso Moralejo, R. García Luján, P. Benavides Mañas, A. López Encuentra (Madrid, Spain). Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC). Eur Respir J 2010; 36: Suppl. 54, 3222
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009
Prognostic value study of lung cancer molecular markers and value of mitochondrial activity in resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Actual challenges in thoracic surgery
Year: 2010
Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Staging of lung cancer
Year: 2010
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
How to treat a T1-T3N0 non-small cell lung cancer (NSCLC) with isolated brain metastasis
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
Quantification of telomerase activity is important in predicting prognosis of patients with non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 482s
Year: 2005
Radiotherapy for stage III non-small cell lung cancer (NSCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Treatment of non-small cell lung cancer (NSCLC) - the state of the art and beyond
Source: International Congress 2017 – State of the art session: "Lung cancer"
Year: 2017
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC)
Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept